70 related articles for article (PubMed ID: 12552235)
1. Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model.
Nguyen D; Emond C; Leclerc Y; Sherman I; Dube P
Med Sci Monit; 2003 Jan; 9(1):BR37-42. PubMed ID: 12552235
[TBL] [Abstract][Full Text] [Related]
2. A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat.
Bendavid Y; Leblond FA; Dubé P
Med Sci Monit; 2005 Jan; 11(1):BR1-5. PubMed ID: 15614183
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Horton TM; Blaney SM; Langevin AM; Kuhn J; Kamen B; Berg SL; Bernstein M; Weitman S
Clin Cancer Res; 2005 Mar; 11(5):1884-9. PubMed ID: 15756014
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
5. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Beale P; Judson I; Hanwell J; Berry C; Aherne W; Hickish T; Martin P; Walker M
Cancer Chemother Pharmacol; 1998; 42(1):71-6. PubMed ID: 9619761
[TBL] [Abstract][Full Text] [Related]
6. The importance of p53-independent apoptosis in the intestinal toxicity induced by raltitrexed (ZD1694, Tomudex): genetic differences between BALB/c and DBA/2 mice.
Pritchard DM; Bower L; Potten CS; Jackman AL; Hickman JA
Clin Cancer Res; 2000 Nov; 6(11):4389-95. PubMed ID: 11106258
[TBL] [Abstract][Full Text] [Related]
7. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
Clarke SJ; Farrugia DC; Aherne GW; Pritchard DM; Benstead J; Jackman AL
Clin Cancer Res; 2000 Jan; 6(1):285-96. PubMed ID: 10656460
[TBL] [Abstract][Full Text] [Related]
8. Clinical and preclinical pharmacokinetics of raltitrexed.
Clarke SJ; Beale PJ; Rivory LP
Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
10. The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
Widemann BC; Balis FM; Godwin KS; McCully C; Adamson PC
Cancer Chemother Pharmacol; 1999; 44(6):439-43. PubMed ID: 10550563
[TBL] [Abstract][Full Text] [Related]
11. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
Judson I; Maughan T; Beale P; Primrose J; Hoskin P; Hanwell J; Berry C; Walker M; Sutcliffe F
Br J Cancer; 1998 Nov; 78(9):1188-93. PubMed ID: 9820178
[TBL] [Abstract][Full Text] [Related]
12. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
13. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
Hendricksen K; Moonen PM; van der Heijden AG; Molkenboer-Kuenen J; Hulsbergen-van de Kaa CA; Witjes JA
Clin Cancer Res; 2006 Apr; 12(8):2597-601. PubMed ID: 16638871
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
15. NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.
Irwin RD
Toxic Rep Ser; 2006 Jul; (48):1-73, A1-H10. PubMed ID: 17160105
[TBL] [Abstract][Full Text] [Related]
16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
17. NTP technical report on the toxicity studies of p-tert-butylcatechol (CAS No. 98-29-3) administered in feed to F344/N rats and B6C3F1 mice.
Dunnick J
Toxic Rep Ser; 2002 Nov; (70):5-51. PubMed ID: 12592414
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Artery and Peripheral Vein Pharmacokinetics of Raltitrexed in Swine After the Administration of a Hepatic Arterial Infusion.
Zhu L; Zheng N; Li X; Zhang X
Curr Drug Metab; 2019; 20(7):601-608. PubMed ID: 31237202
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
